Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns
09:58am, Tuesday, 07'th Apr 2026
AbbVie (NYSE:ABBV | ABBV Price Prediction) stock has pulled back 12% over the past month, sliding to around $204.
The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.
09:53am, Tuesday, 07'th Apr 2026
More than 300,000 Americans use a medication called Humira. Most of them are paying far too much for it.
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
09:00am, Tuesday, 07'th Apr 2026
The Allergan Medical Institute (AMI) Austin location strengthens the national training network with comprehensive, hands-on education. The Orange County and Atlanta AMI centers continue delivering bes
Should You Buy AbbVie Stock Before April 29?
06:45am, Tuesday, 07'th Apr 2026
AbbVie's growth rate has been impressive given the headwinds it has faced. This year, it's forecasting a significant increase in its earnings.
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
06:46pm, Monday, 06'th Apr 2026
In the most recent trading session, AbbVie (ABBV) closed at $206.69, indicating a -1.03% shift from the previous trading day.
AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation
12:29pm, Monday, 06'th Apr 2026
AbbVie remains a 'Buy,' with valuation and forward EPS growth supporting the thesis despite recent sector weakness and an 8% YTD decline. Q4 results exceeded expectations: non-GAAP EPS of $2.71 and re
High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout
12:15pm, Monday, 06'th Apr 2026
Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two very different pharmaceutical stories.
Here's Why AbbVie (ABBV) is a Strong Value Stock
10:40am, Monday, 06'th Apr 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?
09:16am, Monday, 06'th Apr 2026
ABBV heads into Q1 earnings with Skyrizi and Rinvoq in focus as Humira declines, while growth from new indications and market share gains is under watch.
Leo Wealth LLC Raises Holdings in AbbVie Inc. $ABBV
07:15am, Monday, 06'th Apr 2026
Leo Wealth LLC increased its stake in shares of AbbVie Inc. (NYSE: ABBV) by 21.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). T
Savvy Advisors Inc. Buys 6,646 Shares of AbbVie Inc. $ABBV
07:24am, Sunday, 05'th Apr 2026
Savvy Advisors Inc. boosted its stake in AbbVie Inc. (NYSE: ABBV) by 22.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 36,568 shares of t
2,593 Shares in AbbVie Inc. $ABBV Acquired by ASL Financial LLC
03:39am, Saturday, 04'th Apr 2026
ASL Financial LLC acquired a new stake in AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,59
Dorato Capital Management Buys Shares of 4,126 AbbVie Inc. $ABBV
04:50am, Friday, 03'rd Apr 2026
Dorato Capital Management purchased a new position in AbbVie Inc. (NYSE: ABBV) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 4,126 shares of th
2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory
05:32pm, Thursday, 02'nd Apr 2026
Healthcare is a defensive sector worth looking into when the going gets rough. These two pharmaceutical leaders have strong businesses and attractive dividend programs.
Global pharma companies that have publicly announced Trump drug pricing agreements
02:59pm, Thursday, 02'nd Apr 2026
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye
